Synapse - Find an Expert

302 Results

Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19

Journal Article

Laurence, J.; Mulvey, J. J.; Seshadri, M.; Racanelli, A.; Harp, J.; Schenck, E. J.; Zappetti, D.; Horn, E. M.; Magro, C. M.
Clinical Immunology (2020)

Fulltext@MSK | Save

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: A randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Journal Article

Landgren, C. O.; Chari, A.; Cohen, Y. C.; Spencer, A.; Voorhees, P.; Estell, J. A.; Sandhu, I.; Jenner, M. W.; Williams, C.; Cavo, M.; more...
Leukemia (2020)

Fulltext@MSK | Save

Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?

Research Letter

Nawar, T.; Morjaria, S.; Kaltsas, A.; Patel, D.; Perez-Johnston, R.; Daniyan, A. F.; Mailankody, S.; Parameswaran, R.
American Journal of Hematology (2020)

Fulltext@MSK | Save

Consensus recommendations for management and counseling of adverse events associated with lorlatinib: A guide for healthcare practitioners

Guidelines

Reed, M.; Rosales, A. L. S.; Chioda, M. D.; Parker, L.; Devgan, G.; Kettle, J.
Advances in Therapy (2020)

Fulltext@MSK | Save

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: A multicentre, open-label, phase 1 study

Journal Article

Tan, D. S. W.; Leighl, N. B.; Riely, G. J.; Yang, J. C. H.; Sequist, L. V.; Wolf, J.; Seto, T.; Felip, E.; Aix, S. P.; Jonnaert, M.; more...
The Lancet Respiratory Medicine (2020)

Fulltext@MSK | Save

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial

Journal Article

Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
Lancet Oncology (2020)

Fulltext@MSK | Save

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): Post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

Journal Article

Ledermann, J. A.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
Lancet Oncology (2020)

Fulltext@MSK | Save

Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia

Journal Article

Shah, N. N.; Bhojwani, D.; August, K.; Baruchel, A.; Bertrand, Y.; Boklan, J.; Dalla-Pozza, L.; Dennis, R.; Hijiya, N.; Locatelli, F.; more...
Pediatric Blood and Cancer (2020)

Fulltext@MSK | Save

A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer